By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
News for IndiaNews for IndiaNews for India
  • Home
  • Posts
  • Search Page
  • About us
Reading: Stocks to buy: ABB to Glenmark Pharma – Motilal Oswal bet on these three shares for this week | Stock Market News
Share
Font ResizerAa
News for IndiaNews for India
Font ResizerAa
  • Economics
  • Business
  • Home
  • Categories
    • Business
    • Economics
  • About us
  • Sitemap
Follow US
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
News for India > Business > Stocks to buy: ABB to Glenmark Pharma – Motilal Oswal bet on these three shares for this week | Stock Market News
Business

Stocks to buy: ABB to Glenmark Pharma – Motilal Oswal bet on these three shares for this week | Stock Market News

Last updated: October 16, 2024 8:42 pm
8 months ago
Share
SHARE


Contents
Stocks to buyABB: Buy at ₹8553 | Target Price: ₹9200 | Stop Loss: ₹8200Exide Ind: Buy at ₹530 | Target Price: ₹575 | Stop Loss: ₹505Glenmark Pharma: Buy at ₹1790 | Target Price: ₹1950 | Stop Loss: ₹1720

Indian stock market: Indian stock market benchmarks, the Sensex and Nifty 50, declined for the second straight session on Wednesday, October 16, due to weak global signals. The Sensex dropped 319 points, or 0.39 per cent, to 81,501.36, while the Nifty 50 closed at 24,971.30, down 86 points, or 0.34 per cent.

“Nifty fell below 25000 levels and traded sideways throughout the session closing 86 points down at 24971. Nifty smallcap traded flat while midcap lost 0.3%. Baring Oil & Gas, Realty, and Financials, all sectors ended in red. Consumer durable companies were in focus especially the White Goods after the government received applications from 38 companies with a proposed investment of ₹4,121 crore in the third phase of the PLI scheme for air-conditioners and LED lights. HDFC AMC gained significantly upon strong Q2 results which pushed other AMC stocks too. Markets are consolidating and witnessing a dip at a higher zone amid relentless selling by FIIs ( ₹63875crs in Oct so far) & muted results from index heavyweights. We expect this consolidation to continue amid mixed global cues and a lack of domestic triggers. Index-heavy weights like Infosys, Axis Bank, LTI Mindtree, Wipro, and Nestle are likely to be in focus as they announce their Q2 number on Thursday. Also globally, the focus will be on Europe’s interest rate decision along with inflation numbers. Apart from that US Retail Sales and China Q3 GDP data will also be keenly watched,” said Siddhartha Khemka, Head – Research, Wealth Management, Motilal Oswal Financial Services Ltd.

Brokerage firm Motilal Oswal has recommended three stocks – ABB, Exide Ind, and Glenmark Pharma – to buy this week with decent upside potential.

Stocks to buy

ABB: Buy at ₹8553 | Target Price: ₹9200 | Stop Loss: ₹8200

ABB gave range breakout on weekly scale after twelve weeks and formed a strong bullish candle. On daily scale the stock is forming higher lows from past few days and holding well above its short term moving averages. Momentum oscillator RSI is also moving northward on weekly scale which indicates momentum to continue in coming sessions and good buying interest is visible across Capital space. Thus looking at the overall chart structure we are recommending to buy the stock with keeping stop loss below 8200 levels on closing basis for a target towards 9200 zones.

Exide Ind: Buy at ₹530 | Target Price: ₹575 | Stop Loss: ₹505

Exide Ind has formed a strong base on weekly scale near 500 levels and gave consolidation breakout on weekly scale. It formed a strong bullish candle with long lower shadow on weekly scale as buying is visible at lower zones. On daily scale the stock retested the previous breakout zone and holding well above is 50DEMA. Strong outperformance is seen in last few days and stock holding well in spite of market volatility. Thus we are recommending to buy the stock with keeping stop loss below 505 levels on closing basis for a target towards 575 zones.

Glenmark Pharma: Buy at ₹1790 | Target Price: ₹1950 | Stop Loss: ₹1720

The stock is trading at life time high territory and holding well above 1750 zones. Technically the stock gave channel breakout on weekly scale after seven weeks and formed a strong bullish candle with highest close. On daily scale as well the stock formed a bullish candle and strong buying interest visible across Pharma space. Looking at the overall chart structure the stock is likely to outperform with Pharma space and thus recommending to buy the stock with keeping stop loss below 1720 levels on closing basis for a new life time high target towards 1950 zones.

Disclaimer: The views and recommendations provided in this analysis are those of individual analysts or broking companies, not Mint. We strongly advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and individual circumstances may vary.



Source link

You Might Also Like

LGT Wealth’s Chirag Doshi recommends India bond investors to buy 5-10 year notes amid RBI rate cut expectations | Stock Market News

Wall Street week ahead: Spotlight on jobs data, Jerome Powell’s speech, manufacturing& services PMIs | Stock Market News

Wall St Week Ahead-Jobs data, tax bill, trade on tap for rebounding US stocks | Stock Market News

GIFT Nifty sets all-time high monthly turnover of $102.35 billion in May 2025 | Stock Market News

Gold’s rally broke down in May. It’s still doing better than stocks.

TAGGED:ABBBuy or sellBuy or sell stocksExide IndGlenmark PharmaIndian stock marketMotilal OswalNifty50sensexstocks to buy
Share This Article
Facebook Twitter Email Print
Previous Article Morgan Stanley tops estimates on better-than-expected wealth management, trading and banking results
Next Article Stocks making the biggest moves premarket: Morgan Stanley, Cisco, ASML and more

We influence 20 million users and is the number one business and technology news network on the planet.

Find Us on Socials

News for IndiaNews for India
© Wealth Wave Designed by Preet Patel. All Rights Reserved.
  • BUSINESS